Allergy Therapeutics (AGY) RNS Announcements

Add to Alert list
Date Time Source Announcement
19 Dec 2024 01:41 PM
RNS
Exercise of Options and Total Voting Rights
17 Dec 2024 04:19 PM
RNS
Block Listing Interim Review
16 Dec 2024 03:33 PM
RNS
Result of Annual General Meeting
04 Dec 2024 07:00 AM
RNS
Positive Interim Data from PROTECT Trial
27 Nov 2024 07:00 AM
RNS
First Patient Dosed in G308 Paediatric Trial
25 Nov 2024 07:00 AM
RNS
Submission of MAA for Grass MATA MPL
21 Nov 2024 07:00 AM
RNS
Notice of 2024 Annual General Meeting
06 Nov 2024 07:00 AM
RNS
Audited Preliminary Results 2024
21 Oct 2024 07:00 AM
RNS
Commencement of Phase III Paediatric Trial
16 Oct 2024 07:00 AM
RNS
Update on funding
01 Oct 2024 07:00 AM
RNS
Update on funding and preliminary results
17 Sep 2024 07:00 AM
RNS
Progression of patient cohorts in PROTECT Trial
27 Aug 2024 07:00 AM
RNS
Update on funding
22 Jul 2024 07:01 AM
RNS
Trading update for the year ended 30 June 2024
22 Jul 2024 07:00 AM
RNS
Appointment of Nominated Adviser and Sole Broker
04 Jul 2024 02:22 PM
RNS
Launch of new Company Long Term Incentive Plan
27 Jun 2024 07:00 AM
RNS
Appointment of Non-Executive Director
10 Jun 2024 07:00 AM
RNS
Progression of patient cohorts in PROTECT Trial
03 Jun 2024 07:00 AM
RNS
Successful meetings with Paul Ehrlich Institut
31 May 2024 07:00 AM
RNS
Allergy Therapeutics presents findings at EAACI
07 May 2024 07:00 AM
RNS
Further detail from G306 Phase III field trial
03 Apr 2024 07:00 AM
RNS
Director Resignation
27 Mar 2024 07:00 AM
RNS
Update on funding
27 Mar 2024 07:00 AM
RNS
Interim Results for six months ended 31 Dec 2023
12 Mar 2024 08:59 AM
RNS
VLP Peanut PROTECT Trial Update
12 Mar 2024 07:00 AM
RNS
VLP Peanut PROTECT Trial Update
11 Mar 2024 07:00 AM
RNS
Appointment of Shaun Furlong to Board of Directors
08 Mar 2024 01:49 PM
RNS
Result of AGM
14 Feb 2024 07:00 AM
RNS
Half-Year Trading Update 2024
09 Feb 2024 03:07 PM
RNS
Notice of 2023 Annual General Meeting
30 Jan 2024 07:30 AM
RNS
Restoration - Allergy Therapeutics plc
30 Jan 2024 07:00 AM
RNS
Publication of Annual Report and Accounts 2023
04 Jan 2024 12:29 PM
RNS
Total Voting Rights
02 Jan 2024 07:30 AM
RNS
Suspension - Allergy Therapeutics plc
27 Dec 2023 12:01 PM
RNS
Amendment to existing Facility Agreement
15 Dec 2023 12:48 PM
RNS
Annual Report and Accounts Delayed
13 Dec 2023 04:54 PM
RNS
PDMR dealing and Total Voting Rights
13 Dec 2023 07:00 AM
RNS
G306 Phase III trial meets key endpoints
11 Dec 2023 07:00 AM
RNS
Update on funding
01 Dec 2023 07:00 AM
RNS
Total Voting Rights
28 Nov 2023 03:03 PM
RNS
Holding(s) in Company
14 Nov 2023 07:00 AM
RNS
G306 Grass Phase III trial meets primary endpoint
10 Nov 2023 02:39 PM
RNS
Form 8.5 (EPT/RI)
10 Nov 2023 01:22 PM
RNS
Director/PCA Dealing
10 Nov 2023 01:11 PM
RNS
Holding(s) in Company
10 Nov 2023 07:00 AM
RNS
Offer Closure
09 Nov 2023 10:48 AM
RNS
Exercise of Options and Total Voting Rights
09 Nov 2023 09:24 AM
RNS
Form 8.5 (EPT/RI)
09 Nov 2023 09:15 AM
RNS
Form 8.5 (EPT/NON-RI)
08 Nov 2023 10:45 AM
RNS
Form 8.5 (EPT/RI)
UK 100

Latest directors dealings